Maintenance of peritoneal catheter function by the intraperitoneal administration of 32% dextran 70.

C E Pfeifle, S B Howell, I S Abramson, M Markman
{"title":"Maintenance of peritoneal catheter function by the intraperitoneal administration of 32% dextran 70.","authors":"C E Pfeifle,&nbsp;S B Howell,&nbsp;I S Abramson,&nbsp;M Markman","doi":"10.1089/cdd.1985.2.291","DOIUrl":null,"url":null,"abstract":"<p><p>Thirty-two percent dextran 70 was administered to 53 patients receiving intraperitoneal (i.p.) chemotherapy in an attempt to better maintain catheter function. One hundred milliliters of 32% dextran 70 was administered i.p. at the time of catheter placement and at the completion of each course of chemotherapy (every 3 to 4 weeks). Analysis of the functional survival of the dextran treated catheters and 20 historical controls was performed. The cumulative probabilities of catheters maintaining bi-directional function in the dextran treated and control groups were 0.75 and 0.50 respectively. This difference was statistically significant at p = 0.051 by two-tailed Wilcoxon analysis. The difference between survival of dextran treated and control catheters increased if patients who received intraperitoneal doxorubicin were factored out (p = 0.035 by two-tailed Wilcoxon analysis). Plasma and peritoneal dextran levels were measured on 9 courses in 8 patients. Dextran was detectable in the peritoneal cavity up to 7 days after administration. The \"apparent half-life\" of dextran 70 in the peritoneal cavity was 36 hours. Plasma dextran concentrations increased for 2 days following i.p. administration and then decreased with an apparent half-life of 36 hours. One patient experienced chills and another had an anaphylactoid reaction following administration of the dextran. This study suggests that i.p. administration of 32% dextran 70 may be an effective means of minimizing peritoneal catheter failures.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 4","pages":"291-303"},"PeriodicalIF":0.0000,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.291","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/cdd.1985.2.291","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Thirty-two percent dextran 70 was administered to 53 patients receiving intraperitoneal (i.p.) chemotherapy in an attempt to better maintain catheter function. One hundred milliliters of 32% dextran 70 was administered i.p. at the time of catheter placement and at the completion of each course of chemotherapy (every 3 to 4 weeks). Analysis of the functional survival of the dextran treated catheters and 20 historical controls was performed. The cumulative probabilities of catheters maintaining bi-directional function in the dextran treated and control groups were 0.75 and 0.50 respectively. This difference was statistically significant at p = 0.051 by two-tailed Wilcoxon analysis. The difference between survival of dextran treated and control catheters increased if patients who received intraperitoneal doxorubicin were factored out (p = 0.035 by two-tailed Wilcoxon analysis). Plasma and peritoneal dextran levels were measured on 9 courses in 8 patients. Dextran was detectable in the peritoneal cavity up to 7 days after administration. The "apparent half-life" of dextran 70 in the peritoneal cavity was 36 hours. Plasma dextran concentrations increased for 2 days following i.p. administration and then decreased with an apparent half-life of 36 hours. One patient experienced chills and another had an anaphylactoid reaction following administration of the dextran. This study suggests that i.p. administration of 32% dextran 70 may be an effective means of minimizing peritoneal catheter failures.

32%葡聚糖70腹腔注射维持腹膜导管功能。
为了更好地维持导管功能,我们给53例接受腹腔化疗的患者注射32%葡聚糖70。在置管时和每个化疗疗程结束时(每3 - 4周)ig 100毫升32%葡聚糖70。分析右旋糖酐治疗导管和20例历史对照的功能存活情况。葡聚糖处理组和对照组维持导管双向功能的累积概率分别为0.75和0.50。经双尾Wilcoxon分析,差异有统计学意义,p = 0.051。如果排除接受阿霉素腹腔注射的患者,右旋糖酐治疗的导管与对照导管的生存率差异增加(双尾Wilcoxon分析p = 0.035)。测定8例患者9个疗程的血浆和腹膜葡聚糖水平。给药后7天腹腔内可检测到葡聚糖。葡聚糖70在腹腔内的“表观半衰期”为36小时。血浆葡聚糖浓度在给药后2天内升高,然后下降,表观半衰期为36小时。一名患者在服用右旋糖酐后出现寒战,另一名患者出现类过敏反应。本研究提示,32%葡聚糖70的静脉滴注可能是减少腹膜导管失败的有效方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信